Phage therapy of E coli infections
AssigneeErytech Pharma
InventorsFlavie Pouillot, Hélène Blois
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims13
An antibacterial composition comprising at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain and a pharmaceutically acceptable excipient or carrier, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto, and said pharmaceutically acceptable excipient or carrier comprising a preservative in an amount effective to preserve the activity of the bacteriophage.
A method of treatment of an infection in a mammal in need thereof, comprising administering to the mammal infected with an Escherichia coli (E. coli) strain an antibacterial composition in an amount effective to treat the E. coli infection, wherein said composition comprises at least one bacteriophage having lytic activity to the E. coli strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto.
A method for improving the condition of a mammal by modifying the microbial flora thereof, comprising administering to the mammal an effective amount of an antibacterial composition, wherein said composition comprises at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto, and said microbial flora comprises the E. coli strain.
A method for decontaminating a material, comprising exposing the material to an amount of an antibacterial composition effective to decontaminate the material, wherein said composition comprises at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto, and said material is contaminated with the E. coli strain.
A method for preparing an antibacterial composition, comprising:
- a) producing at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto;
- and
- b) combining at least said bacteriophage with a pharmaceutically acceptable carrier or excipient, said pharmaceutically acceptable excipient or carrier comprising a preservative in an amount effective to preserve the activity of the bacteriophage.
A method for predicting or determining the efficacy of a bacteriophage therapy in a subject and treating said subject, wherein the method comprises:
- a) determining in vitro a lytic activity of a composition comprising at least one bacteriophage to an E. coli strain from a sample of said subject, said at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain and being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto;
- and
- b) treating the subject with the composition, when in step a) a lytic activity of said composition to at least one E. coli strain from said sample has been determined.
A method for selecting a subject or determining whether a subject is susceptible to benefit from a bacteriophage therapy and treating said subject, wherein the method comprises:
- a) determining a lytic activity of a composition comprising at least one bacteriophage to an E. coli strain from a sample of said subject, said at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain and being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99° A identity thereto;
- and
- b) treating the subject with the composition, when in step a) a lytic activity of said composition to at least one E. coli strain from said sample has been determined.
Dependencies are inferred from the claim text.